SPERO THERAPEUTICS INC (SPRO) Stock News
NASDAQ:SPRO - Nasdaq - US84833T1034 - Common Stock - Currency: USD
SPRO Latest News, Press Relases and Analysis
Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone
Spero Therapeutics, Inc. (NASDAQ:SPRO) saw its stock surge by 240% on May 28 following the company’s announcement of the successful completion of the pivotal Phase 3 PIVOT-PO trial for tebipenem HBr, an investigational oral antibiotic intended for use in treating complicated urinary tract infections. The Phase 3 study, conducted in collaboration with development partner GSK plc, effectively achieved […]
SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal
SPRO shares surge after GSK-partnered oral drug hits phase III goal early, paving the way for FDA filing and a shift in cUTI treatment options.
SPRO Stock Earnings: Spero Therapeutics Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Spero Therapeutics (NASDAQ:SPRO) just reported results for the second quarter o...
GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled
The early stop follows the trial meeting its primary endpoint of non-inferiority of Tebipenem HBr compared to an intravenous medicine in hospitalised adult patients with cUTI.
GSK Stops Antibiotic Trial Early After Seeing Positive Results
GSK Plc halted a trial following positive results for an oral antibiotic to treat complicated urinary tract infections that could replace an intravenous medicine that is typically used.
Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update
Pre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI), including...
UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
uniQure (QURE) delivered earnings and revenue surprises of 23.36% and 73.88%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: QURE
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates
Avidity Biosciences (RNA) delivered earnings and revenue surprises of -2.27% and 46.68%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: RNA
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of 23.08% and 13.32%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: MIRM
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on...
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates
Spero Therapeutics (SPRO) delivered earnings and revenue surprises of -8.57% and 21.32%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Mentions: NRIX
Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update
Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be...
UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical...
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes
Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership...
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update
Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending...
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
In vitro data on SPR719 show low propensity for resistance development in NTM-PD MAC strains when administered as a single agent and in combination with...
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy
Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR719 (active...